Mural Oncology plc/MURA

$3.57

-5.05%
-
1D1W1MYTD1YMAX

About Mural Oncology plc

Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.

Ticker

MURA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

-

Employees

117

Headquarters

Dublin, Ireland

Website

-

MURA Metrics

BasicAdvanced
$69.21M
Market cap
-
P/E ratio
-$12.43
EPS
-
Beta
-
Dividend rate
$69.21M
$17.00
$3.23
258.14K
9.558
0.259
0.262
-9.29%

What the Analysts think about MURA

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
264.15% upside
High $13.00
Low $13.00
$3.57
Current price
$13.00
Average price target

MURA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-59.5M
16.21%
Profit margin
0%
-

MURA Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q1 24
Actual
-
Expected
-$2.66
Surprise
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Mural Oncology plc stock?

Mural Oncology plc (MURA) has a market cap of $69.21M as of April 19, 2024.

What is the P/E ratio for Mural Oncology plc stock?

The price to earnings (P/E) ratio for Mural Oncology plc (MURA) stock is 0 as of April 19, 2024.

Does Mural Oncology plc stock pay dividends?

No, Mural Oncology plc (MURA) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Mural Oncology plc dividend payment date?

Mural Oncology plc (MURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Mural Oncology plc?

Mural Oncology plc (MURA) does not currently have a Beta indicator.

What is the Mural Oncology plc stock price target?

The target price for Mural Oncology plc (MURA) stock is $13, which is 264.15% above the current price of $3.57. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Mural Oncology plc stock

Buy or sell Mural Oncology plc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing